Clinical Trial: CBD Dosing Reduces Anxiety and Tremor in Parkinson's Patients

Thursday, 16 January 2020

Sao Carlos, Brazil: Cannabidiol administration is associated with both decreased anxiety and tremor amplitude in patients with Parkinson's disease (PD), according to clinical trial data published in the Journal of Psychopharmacology.

A team of Brazilian researchers assessed the efficacy of a 300mg dose of CBD in patients with PD in a randomized, placebo-controlled model. Acute CBD administration was associated with a statistically significant reduction in experimentally-induced anxiety and tremor.

A previous trial similarly reported that CBD was anxiolytic at doses of 300mg in healthy volunteers, but that it was not so at higher (600mg) and lower doses (150mg).

Observational trial data has previously reported that inhaled cannabis is associated with improvements in multiple PD symptoms, including tremor, rigidity, and bradykinsea.

Full text of the study, "Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson's disease," appears in the Journal of Psychopharmacology. Additional information on cannabinoids and PD is available from NORML.